"1"^^ . . "-\u03B3--N-methyl-benzenepropanamine hydrochloride"@en . . . "73410"^^ . . . . . . "1"^^ . . . . "4500" . "Nisoxetine, originally synthesized in the Lilly research laboratories during the early 1970s, is a potent and selective inhibitor for the reuptake of norepinephrine (noradrenaline) into synapses. It currently has no clinical applications in humans, although it was originally researched as an antidepressant. Nisoxetine is now widely used in scientific research as a standard selective norepinephrine reuptake inhibitor. It has been used to research obesity and energy balance, and exerts some local analgesia effects. Researchers have attempted to use a carbon-labeled form of nisoxetine for positron emission tomography (PET) imaging of the norepinephrine transporter (NET), with little success. However, it seems that tritium labeled nisoxetine (3H-nisoxetine, 3H-NIS) is a useful radioligand for labeling norepinephrine uptake sites in vitro, which nisoxetine and other antagonists for NET are able to inhibit."@en . "LY-94939,"@en . . . . . . . "295467" . "changed"@en . . . . . . . . "4344"^^ . "53179-07-0" . . "16454909"^^ . . "17"^^ . "492910405"^^ . . "\uB2C8\uC18D\uC138\uD2F4"@ko . . . . . . . "Never marketed"@en . . "2"^^ . . . . . . . . . "-3"^^ . . . . . . . . . . . . . . . . "\uB2C8\uC18D\uC138\uD2F4(Nisoxetine, LY-94939)\uC740 \uB178\uB974\uC5D0\uD53C\uB124\uD504\uB9B0\uC758 \uC7AC\uD761\uC218\uB97C \uC5B5\uC81C\uD558\uB294 \uC57D\uC774\uB2E4. \uC774\uC131\uC9C8\uCCB4\uC640 \uD568\uAED8 \uB77C\uC138\uBBF9 \uD63C\uD569\uBB3C\uC774\uB2E4. \uCD5C\uADFC\uC5D0\uB294 \uB2C8\uC18D\uC138\uD2F4\uC744 \uC0AC\uB78C\uC5D0\uAC8C \uD22C\uC5EC\uD558\uC9C0 \uC54A\uC73C\uB098, NRI \uC6D0\uB798 \uC6B0\uC6B8\uC99D \uCE58\uB8CC\uC81C\uB85C\uC11C \uC5F0\uAD6C\uC640 \uD604\uC7AC NRL \uC120\uBCC4 \uAE30\uC900\uC73C\uB85C\uC11C\uC758 \uACFC\uD559 \uC5F0\uAD6C\uC5D0 \uB110\uB9AC \uC0AC\uC6A9\uB41C\uB2E4."@ko . . . . "Nisoxetine, originally synthesized in the Lilly research laboratories during the early 1970s, is a potent and selective inhibitor for the reuptake of norepinephrine (noradrenaline) into synapses. It currently has no clinical applications in humans, although it was originally researched as an antidepressant. Nisoxetine is now widely used in scientific research as a standard selective norepinephrine reuptake inhibitor. It has been used to research obesity and energy balance, and exerts some local analgesia effects."@en . . . . "changed"@en . "CNCCCOC2=CC=CC=C2OC"@en . . . . . "17NV064B2D" . . . "175"^^ . . . . . . . . . "17"^^ . "53179"^^ . . "D05173" . . . . "24615"^^ . . . . . . . . "D05173"@en . . "73410" . . . . . . . . . . . . . "None"@en . . . . . "21"^^ . . . "295467"^^ . . . . "Nisoxetin (LY-94939) ist ein Selektiver Noradrenalin-Wiederaufnahmehemmer (NARI). Urspr\u00FCnglich wurde es als Antidepressivum entwickelt, kam aber nicht \u00FCber die Entwicklungsstufe hinaus. Es gilt allerdings in der wissenschaftlichen Forschung als \u201EStandard-NARI\u201C und wird als solches h\u00E4ufig verwendet. Es wird als Racemat eingesetzt."@de . . . . "4637"^^ . . . "\uB2C8\uC18D\uC138\uD2F4(Nisoxetine, LY-94939)\uC740 \uB178\uB974\uC5D0\uD53C\uB124\uD504\uB9B0\uC758 \uC7AC\uD761\uC218\uB97C \uC5B5\uC81C\uD558\uB294 \uC57D\uC774\uB2E4. \uC774\uC131\uC9C8\uCCB4\uC640 \uD568\uAED8 \uB77C\uC138\uBBF9 \uD63C\uD569\uBB3C\uC774\uB2E4. \uCD5C\uADFC\uC5D0\uB294 \uB2C8\uC18D\uC138\uD2F4\uC744 \uC0AC\uB78C\uC5D0\uAC8C \uD22C\uC5EC\uD558\uC9C0 \uC54A\uC73C\uB098, NRI \uC6D0\uB798 \uC6B0\uC6B8\uC99D \uCE58\uB8CC\uC81C\uB85C\uC11C \uC5F0\uAD6C\uC640 \uD604\uC7AC NRL \uC120\uBCC4 \uAE30\uC900\uC73C\uB85C\uC11C\uC758 \uACFC\uD559 \uC5F0\uAD6C\uC5D0 \uB110\uB9AC \uC0AC\uC6A9\uB41C\uB2E4."@ko . "Nisoxetin (LY-94939) ist ein Selektiver Noradrenalin-Wiederaufnahmehemmer (NARI). Urspr\u00FCnglich wurde es als Antidepressivum entwickelt, kam aber nicht \u00FCber die Entwicklungsstufe hinaus. Es gilt allerdings in der wissenschaftlichen Forschung als \u201EStandard-NARI\u201C und wird als solches h\u00E4ufig verwendet. Es wird als Racemat eingesetzt."@de . . . . "Nisoxetine"@en . . . . . "4500"^^ . . . . "Nisoxetin"@de . . . . . . . . . . . . "1107676221"^^ . . "ITJNARMNRKSWTA-UHFFFAOYSA-N"@en . . . . .